Who we are The Scientific Institute for Research, Hospitalization and Health Care (IRCCS) San Raffaele Pisana is devoted to guarantee excellent care in many fields of rehabilitation. The institution performs an intense and qualified research activity thanks to the support of a modern Research Centre and an Interinstitutional Multidisciplinary Biobank (BioBIM), a cutting-edge facility for translational research in the medical area, whose multidisciplinary organization allows pluripotency, flexibility and the involvement of several areas of expertise. The BioBIM wide network of collaborations strengthens the possibility of promoting cultural exchange at a national and international level, supporting projects, multicentre protocols and research agreements.

Our role in REVERT San Raffaele will function as Project Coordinator ensuring a good group dynamic, providing opportunities for extracting the best from the intellectual capacity and expertise of the partners and acting as the intermediary between the Beneficiaries and the Funding Authority. In addition to its Coordinator responsibilities San Raffaele will jointly function with the infrastructure design, which will be implemented as an ICT framework for integrating, extracting and harmonizing data from the different databases coordinated in the project and to be used in the decision support systems being developed to predict patient responses to combinatorial therapies for mCRC care.

To build an AI-based computational framework for the construction of clinical decision-making systems that provide probabilistic information in terms of risk definition, therapeutic response, prognosis, or disease outcome in patients with chronic disorders.

Fiorella Guadagni

Patrizia Ferroni

Antonella Spila

Who we are ProMIS - Mattone Internazionale Salute, is an institutionalised network, led by Veneto Region, involving the Ministry of Health and all the Italian Regions/Autonomous Provinces. Since 2011, ProMIS has been promoting opportunities of cooperation among the Italian regions in the framework of European funds and opportunities about social and health issues. ProMIS main tasks are: a) offering opportunities for information, dissemination and training; b) fostering the capacity building of public administrations; c) responding the needs jointly expressed by the regions and local social-healthcare authorities; d) stimulating the participation of Italian clusters to national and European initiatives; e) supporting the regions and other public administrations in transferring knowledge and competences at EU level.

Our role in REVERT ProMIS applies its expertise on dissemination and communication at European level. The objectives are:

  • to disseminate project knowledge, standards and results during the project duration
  • to disseminate to relevant stakeholders and the general public information about innovative alternative therapy to treat mCRC patients with, the project outcomes and current results
  • to create an effective and tangible dissemination and communication plan
  • to develop a strategy for commercial exploitation of the result

Lisa Leonardini

Monica Manfrin

Lola Patumi

Nicola Scomparin

Paola Semisa

Who we are Biovariance GmbH was founded in 2013 and is headquartered in Waldsassen, Germany. Its multidisciplinary team develops innovative AI solutions for precision medicine in the healthcare, pharma and biotech sectors. In cooperation with physicians, BioVariance offers long-term monitoring of molecular changes in patients to predict the effectiveness, side effects and drug interactions, thereby helping to determine optimal medication and dosage. To achieve this, state-of-the-art automatization and parallelization techniques, machine learning, and mathematical algorithms are combined to analyze complex biomedical data.

Our role in REVERT BioVariance applies its expertise on the development of predictive models for the stratification of patients according to the clinical outcome of a medical treatment, based on the patients’ molecular data. Suitable models and AI methods are selected with regard to traceability for the identification and validation of molecular signatures.

Our aim is to reveal the mechanisms behind therapy efficiency in colorectal cancer to enable the identification of the best possible treatment for each individual patient.

Tanja Lucas

Alexander Maurer

Who we are IMAGO-MOL, the only dedicated medical imaging cluster in Romania and European Union is a non-governmental organization whose objectives are to support the growth of scientific and economic competitiveness of its members in North East Region The focus areas are medical imaging and connected fields mainly oriented towards digital health. Established in 2012, Imago-Mol Cluster gathers under its umbrella a number of 35 members: universities, R&D institutes, healthcare, ICT and tech SMEs, public and private hospitals, promoters of regional development.

Our role in REVERT As a cluster management entity, we will ensure the coordination and harmonization in terms of project management, communication and dissemination of the project for our affiliates (linked third parties) that will directly participate in the project in both IT and medical activities. Moreover, our IT experts will be directly involved in the development of the REVERT DataBase, the innovative AI based decision support system and the predictive model mobile app that will facilitate the access to the system to the end users.

As precision medicine is one of the focus area of our cluster’s efforts, we believe that REVERT will be our first joint effort to contribute to an European model of AI based support decision system that will improve the personalized therapeutic approach of CRC.

Mihaela Breaban

Alina Capitanu

Adrian Iftene

Carmen Mihai

Cipriana Stefanescu

Who we are University of Rome “Tor Vergata” embraces multidisciplinary competences (from computer science to human sciences) in a unique environment that supports cross-fertilization between Medicine and Artificial Intelligence. Within the Departments of Systems Medicine and of Industrial Engineering, the Medical Oncology Unit and the Artificial Intelligence Unit are involved in clinical programs emphasizing the diagnosis and treatment of solid tumors. The Units provide a full range of "standard" and "innovative" protocols based on Artificial Intelligence algorithms identified within diagnostic and therapeutic pathways involving a close collaboration between the specialists of the numerous disciplines present at the Tor Vergata Clinical Center (PTV).

Our role in REVERT The REVERT project will address the specific challenge of understanding the pathophysiology of mCRC in patients responding well or poorly to therapies, to design optimal strategies for mCRC treatment on a case by case basis, by evaluating combinational therapies and modulating therapeutic interventions depending on the patient’s individual characteristics. By analysing the responses to already authorized molecular drugs for mCRC, an AI-based decision support system incorporating available large databases with new biomarkers and gender differences will be implemented to evaluate its impact on survival and quality of life in a prospective clinical trial.

Mario Roselli

Fabio Massimo Zanzotto

Who we are IBBL (Integrated BioBank of Luxembourg) is an integrated research infrastructure organised within the Luxembourg Institute of Health (LIH) and dedicated to supporting biomedical research for the benefit of patients. IBBL offers biospecimen-related services including the collection, processing, analysis and storage of biological samples and associated data. As a central pillar of the LIH transversal translational medicine vision, IBBL’s mission is to address the biobanking needs of Luxembourg’s hospitals and research institutions, enable national personalised medicine initiatives and support international partners in developing better healthcare solutions. IBBL is ISO 9001:2015 certified and ISO 17025:2005 accredited. Its quality management system is conceived to be compliant with NF S96-900:2011 and ISO 17043:2010.

Our role in REVERT As part of the project, and leveraging on its long-standing expertise in biomarker validation, quality control and standardisation of processing methods, IBBL will be involved in quality assurance and will contribute to the development of Standard Operating Procedures (SOPs) pertaining to pre-analytical and analytical validation protocols to measure classic and novel biomarkers, as well as the elaboration of decision criteria concerning the predictive performance characteristics of CRC biomarkers.

By participating in this highly collaborative and translational project, IBBL aims to reinforce its position as a research infrastructure dedicated to advancing the next generation of personalised cancer therapies.

Fay Betsou

Monica Marchese

Under construction

Under construction